Author

Geert D’Haens 1

1 Academic Medical Center,Amsterdam,Netherlands

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Geert D’Haens, Alessandro Armuzzi, Chinyu Su, Xiang Guo, Irene Modesto, Rajiv Mundayat, David P. Hudesman, Michael Chiorean

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Sarah Harris, William Sandborn, Brian G. Feagan, Stephen B Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong Liu, Douglas C. Wolf, Geert D’Haens

EFFICACY AND IMPROVED HEALTH-RELATED QUALITY OF LIFE AFTER 52-WEEKS OF MIRIKIZUMAB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: AN UPDATE FROM A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

Marc Ferrante, William Sandborn, Bal R Bandhari, Geert D’Haens, Brian G. Feagan, Michael Durante, Vipin Arora, Jay Tuttle, April Naegeli

Histologic remission and mucosal healing in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis

Rish K. Pai, James Canavan, Jay Tuttle, Michael Durante, Vipin Arora, Catherine Milch, Noam Harpaz, Geert D’Haens, Bruce E. Sands, William Sandborn

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Silvio Danese, Brian G. Feagan, Douglas C. Wolf, Stephen B Hanauer, Igor Jovanovic, Subrata Ghosh, AnnKatrin Petersen, Steven Y Hua, Ji Hwan Lee, Lorna Charles, Denesh Chitkara, William Sandborn, Geert D’Haens

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Geert D’Haens

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Geert D’Haens, Omoniyi J. Adedokun, Silvio Danese, Severine Vermeire, Julian Panés, Axel Dignass, Fernando Jose Magro Dias, Maciek Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Daniel R. Gaya, Laurent Peyrin-Biroulet

REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS

Tessa Straatmijer, Sara van Gennep, Marjolijn Duijvestein, Cyriel Y. Ponsioen, Krisztina Barbara Gecse, Geert D’Haens, Mark Lowenberg

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

William Sandborn, Julian Panés, Geert D’Haens, Bruce E. Sands, Remo Panaccione, Siew Cheng Ng, Thomas V Jones, Nervin Lawendy, nicole kulisek, Rajiv Mundayat, Chinyu Su

Item 1 - 9 / 9
1